Morgan Stanley Maintains Equal-Weight on Avantor, Raises Price Target to $15
Morgan Stanley analyst Tejas Savant maintains Avantor (NYSE:AVTR) with a Equal-Weight and raises the price target from $14 to $15.
Stocks · News reference
Barclays Maintains Underweight on Avantor, Raises Price Target to $15
Barclays analyst Luke Sergott maintains Avantor (NYSE:AVTR) with a Underweight and raises the price target from $13 to $15.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
TD Cowen Maintains Hold on Avantor, Raises Price Target to $17
TD Cowen analyst Dan Brennan maintains Avantor (NYSE:AVTR) with a Hold and raises the price target from $15 to $17.
Global Methyl Grignard Reagent Market - Strategic Forecast, 2026-2032 | Pharmaceutical Demand, AI Process Control, and Resilient Supply Chains Unlock Growth Opportunities
The global methyl Grignard reagent market is experiencing growth driven by pharmaceutical demand, AI-enabled process control, and resilient supply chains. The market emphasizes safety, quality consistency, and reliable supply across regions, with AI tools improving research and manufacturing operations while maintaining expert oversight. Regional strategies vary based on local infrastructure, regulatory requirements, and technical capabilities.